Safety and Immunogenicity Study of a DNA Priming and MVA Boosting Strategy of HIV Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

March 31, 2013

Study Completion Date

August 31, 2013

Conditions
HIV Infections
Interventions
BIOLOGICAL

DNA HIVIS and MVA-CMDR

600 µg i.d. (separate plasmids pools) of DNA priming at weeks 0, 4 and 12; 108 pfu i.m. MVA boosting at weeks 24 and 36

BIOLOGICAL

DNA HIVIS and MVA-CMDR

1200 µg i.d. (separate plasmids pools) of DNA priming at weeks 0, 4 and 12 ; 108 pfu i.m. MVA boosting at weeks 24 and 36

BIOLOGICAL

Saline solution

2 x 0.1 ml of saline solution i.d at weeks 0, 4 and 12 ; saline solution i.m at weeks 24 and 36

BIOLOGICAL

Saline solution

2 x 0.2 ml of saline solution i.d at weeks 0, 4 and 12 ; saline solution i.m at weeks 24 and 36

Trial Locations (1)

Unknown

Centro de Investigação e Treino em Saúde de Polana Caniço, Maputo

All Listed Sponsors
collaborator

Swedish Institute for Communicable Disease Control, Sweden

UNKNOWN

collaborator

European and Developing Countries Clinical Trials Partnership (EDCTP)

OTHER_GOV

lead

Instituto Nacional de Saúde, Mozambique

OTHER_GOV

NCT01407497 - Safety and Immunogenicity Study of a DNA Priming and MVA Boosting Strategy of HIV Vaccine | Biotech Hunter | Biotech Hunter